Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 151.32 USD 1.02% Market Closed
Market Cap: 364.1B USD
Have any thoughts about
Johnson & Johnson?
Write Note

Gross Margin
Johnson & Johnson

68.3%
Current
70%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
68.3%
=
Gross Profit
61.1B
/
Revenue
89.3B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
Johnson & Johnson
NYSE:JNJ
364B USD
68%
US
Eli Lilly and Co
NYSE:LLY
730.4B USD
82%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK
84%
CH
Roche Holding AG
SIX:ROG
210.1B CHF
74%
CH
Novartis AG
SIX:NOVN
188.5B CHF
76%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
82%
US
Merck & Co Inc
NYSE:MRK
201.7B USD
78%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
68%
US
Pfizer Inc
NYSE:PFE
136.6B USD
75%
FR
Sanofi SA
PAR:SAN
105.5B EUR
70%
No Stocks Found

Johnson & Johnson
Glance View

Economic Moat
Wide
Market Cap
364B USD
Industry
Pharmaceuticals

Founded in 1886, Johnson & Johnson began its journey with a commitment to revolutionizing healthcare, starting with the sterile surgical dressings it produced to reduce infections in hospitals. Over the decades, this vision expanded into a global healthcare powerhouse, intricate in its operation yet unified in its mission to improve lives. Johnson & Johnson's business model is built on three core segments: pharmaceuticals, medical devices, and consumer health products. Each segment harnesses the synergy of innovation, research, and a deep understanding of customer needs. The pharmaceutical division, one of its most robust, thrives on producing treatments for various medical conditions, including immunology, oncology, and neuroscience. It is in this domain that cutting-edge research and development efforts translate into high-margin therapies, driving substantial portions of the company's revenue. Beyond pharmaceuticals, the medical devices segment forms a pillar of Johnson & Johnson's operations, offering a spectrum of products essential for surgeries, orthopedics, and vision care. These devices are integral for modern healthcare practices, with their premium positioning contributing significantly to the company’s financial health. Meanwhile, Johnson & Johnson's consumer health division addresses everyday wellness needs, with iconic brands like Band-Aid, Tylenol, and Neutrogena. This segment leverages global brand recognition and trust to generate steady, albeit lower-margin, income streams. Together, these segments compose a diversified revenue platform, buffered against sector-specific downturns and positioning Johnson & Johnson as a formidable entity in global healthcare markets.

JNJ Intrinsic Value
162.06 USD
Undervaluation 7%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
68.3%
=
Gross Profit
61.1B
/
Revenue
89.3B
What is the Gross Margin of Johnson & Johnson?

Based on Johnson & Johnson's most recent financial statements, the company has Gross Margin of 68.3%.

Back to Top